Next-Generation Imaging

Latest News

FDA approves flotufolastat F 18 for PSMA-PET imaging in prostate cancer
FDA approves flotufolastat F 18 for PSMA-PET imaging in prostate cancer

May 30th 2023

The approval of flotufolastat F 18 (formerly 18F-rhPSMA-7.3) in prostate cancer is based on findings from the phase 3 SPOTLIGHT and LIGHTHOUSE trials.

Study of novel PSMA theranostic shows positive initial safety and efficacy
Study of novel PSMA theranostic shows positive initial safety and efficacy

May 24th 2023

Artificial Intelligence may enhance efficacy of mpMRI in prostate cancer
Artificial Intelligence may enhance efficacy of mpMRI in prostate cancer

May 15th 2023

ARASTEP darolutamide/ADT study in HSPC to use Illuccix to facilitate outcome assessment
ARASTEP darolutamide/ADT study in HSPC to use Illuccix to facilitate outcome assessment

May 8th 2023

PSMA-PET imaging product Illuccix officially launches in Canada for prostate cancer
PSMA-PET imaging product Illuccix officially launches in Canada for prostate cancer

May 5th 2023

Latest CME Events & Activities

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond

View More

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

Updates in Therapeutic Strategies for Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach to Optimal Management of Adverse Effects, featuring Counseling Vignettes

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC

View More

How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer

View More

How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy

View More

Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings

View More

7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

10/21/2023

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

Expert Illustrations & Commentaries™: The Role of Radioligand Therapy in mCRPC and How It Could Impact Your Practice in the Future

View More

7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)

10/21/2023

View More

© 2023 MJH Life Sciences

All rights reserved.